Published in J Natl Cancer Inst on September 01, 1971
A cross-reacting embryonic antigen in the membrane of rat sarcoma cells which is immunogenic in the syngeneic host. Br J Cancer (1973) 1.24
A common tumour specific antigen. II. Further characterization of the whole antigen and of a cross-reacting antigen of normal tissues. Br J Cancer (1974) 1.15
Radioimmunoassay of tumour specific transplantation antigen of a chemically induced rat sarcoma: circulating soluble tumour antigen in tumour bearers. Br J Cancer (1973) 1.08
Assessment of cell-mediated immunity against coxsackievirus B3-induced myocarditis in a primate model (Papio papio). Infect Immun (1981) 1.04
Assessment of coxsackievirus B3 ts mutants for induction of myocarditis in a murine model. Infect Immun (1979) 1.02
Immunogenicity of rat hepatoma membrane fractions. Br J Cancer (1973) 0.95
Temperature-sensitive mutant of coxsackievirus B3 establishes resistance in neonatal mice that protects them during adolescence against coxsackievirus B3-induced myocarditis. Infect Immun (1983) 0.94
Tumor-secific immunity to chemically induced tumors. Evidence for immunologic specificity and shared antigenicity in lymphocyte responses to soluble tumor antigens. J Exp Med (1975) 0.91
Antitumor activity of Listeria monocytogenes on a guinea pig fibrosarcoma. Infect Immun (1979) 0.85
Immunoglobulins associated with human tumours in vivo: IgG concentrations in eluates of colonic carcinomas. Br J Cancer (1980) 0.84
Studies on mouse Moloney virus induced tumours: I. The detection of p30 as a cytotoxic target on murine Moloney leukaemic spleen cells, and on an in vitro Moloney sarcoma line by antibody mediated cytotoxicity. Br J Cancer (1975) 0.83
A human tumour-associated membrane antigen from squamous-cell carcinoma of the lung. Br J Cancer (1980) 0.83
Lymphoproliferative response as an index of cellular immunity in malignant melanoma of the uvea and its correlation with the histological features of the tumour. Br J Ophthalmol (1980) 0.83
Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens. Br J Cancer (1979) 0.82
Cell electrophoresis for diagnostic purposes. I. Diagnostic value of the electrophoretic mobility test (EMT) for the detection of gynaecological malignancies. Br J Cancer (1981) 0.81
The kinetics of T lymphocyte subpopulations in guinea-pigs sensitized with allogeneic transplantation antigens. Clin Exp Immunol (1980) 0.79
Studies of cellular mediated immunity in malignant melanoma patients by Leukocyte Adherence Inhibition Test. Arch Dermatol Res (1980) 0.75
A study of methods for producing cell-free tumour antigen from BP8 mouse ascites tumour. Br J Exp Pathol (1973) 0.75
Leucocyte migration inhibition under agarose versus MEM test for detection of tumour-associated antigens. Br J Cancer (1978) 0.75
Biological activities of solubilized surface antigens of embryonic and polyoma-virus-transformed cells. Br J Cancer (1978) 0.75
Tumour-associated antigens reacting with cytotoxic antibodies in serum of hepatoma-bearing rats. Br J Cancer (1981) 0.75
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med (1988) 7.12
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A (1987) 6.90
A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods (1980) 6.44
Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol (1987) 5.64
Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett (1989) 4.75
Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A (1991) 4.56
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol (1990) 4.36
The macrophage in the persistence and pathogenesis of HIV infection. AIDS (1989) 4.06
Complement fixation on cell surfaces by 19S and 7S antibodies. Science (1965) 4.04
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med (1989) 3.89
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol (1965) 3.42
Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol (1990) 3.26
B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol (1987) 3.18
Rapid quantitation of neutrophil chemotaxis: use of a polyvinylpyrrolidone-free polycarbonate membrane in a multiwell assembly. J Immunol Methods (1980) 3.12
Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol (1988) 2.82
Complement and Hemolysis. Science (1963) 2.73
Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells. J Immunol (1977) 2.73
Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun (1995) 2.52
Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. J Immunol (1981) 2.39
Macrophages in resistance to rickettsial infection: macrophage activation in vitro for killing of Rickettsia tsutsugamushi. J Immunol (1979) 2.34
Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol (1991) 2.30
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. J Immunol (1978) 2.12
Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells. Infect Immun (1980) 2.12
Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol (1989) 2.12
NAP-1 (IL-8) Immunol Today (1990) 2.09
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
Defective tumoricidal capacity of macrophages from C3H/HeJ mice. J Immunol (1978) 2.01
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. J Immunol (1966) 1.95
Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages. J Immunol (1981) 1.94
Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol (1991) 1.92
Macrophage activation for tumor cytotoxicity: induction of tumoricidal macrophages by supernatants of PPD-stimulated Bacillus Calmette-Guérin-immune spleen cell cultures. J Immunol (1977) 1.91
Abnormal monocyte chemotactic response in cancer patients. J Natl Cancer Inst (1974) 1.87
Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science (1994) 1.84
Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc Natl Acad Sci U S A (1989) 1.81
C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. J Immunol (1966) 1.80
Solid phase radioimmunoassay of human beta 1C globulin. Immunochemistry (1970) 1.77
Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst (1972) 1.75
Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst (1974) 1.74
Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser (1994) 1.73
Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes. J Immunol (1990) 1.68
BCG and cancer. N Engl J Med (1974) 1.66
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
Macrophage-HIV interaction: viral isolation and target cell tropism. AIDS (1990) 1.64
Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science (1970) 1.64
Macrophage activation for tumor cytotoxicity: increased lymphokine responsiveness of peritoneal macrophages during acute inflammation. J Immunol (1978) 1.63
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun (1983) 1.60
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4. J Immunol (1971) 1.60
Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell Immunol (1976) 1.58
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol (2001) 1.58
Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages. J Immunol (1994) 1.57
Macrophage activation for tumor cytotoxicity: control of macrophage tumoricidal capacity by the LPS gene. J Immunol (1978) 1.56
Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration. Int J Cancer (1977) 1.56
A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med (1990) 1.53
Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol (1993) 1.53
Secretion by human fibroblasts of monocyte chemoattractant protein-1, the product of gene JE. J Immunol (1990) 1.52
Macrophages cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein (interleukin 8) sequentially in response to stimulation with lipopolysaccharide and zymosan. J Clin Invest (1990) 1.49
Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice. J Immunol (1979) 1.48
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
Colony-stimulating factors. J Am Acad Dermatol (1990) 1.47
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst (1972) 1.47
Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol (1993) 1.45
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44
Synthesis of the first component of human complement in vitro. J Exp Med (1968) 1.44
Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal cells: evidence that one cell may produce both components. J Immunol (1972) 1.44
Macrophage stimulating protein: purification, partial amino acid sequence, and cellular activity. J Exp Med (1991) 1.43
Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem (1993) 1.42
Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst (1974) 1.42
Effects of cell concentration on chemotactic responsiveness of mouse resident peritoneal macrophages. J Reticuloendothel Soc (1981) 1.41
Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol (1981) 1.40
Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science (1988) 1.39
Interaction of BCG-activated macrophages with neoplastic and nonneoplastic cell lines in vitro : quantitation of the cytotoxic reaction by release of tritiated thymidine from prelabeled target cells. J Natl Cancer Inst (1975) 1.38
Macrophage activation for tumor cytotoxicity: tumoricidal activity by macrophages from C3H/HeJ mice requires at least two activation stimuli. Cell Immunol (1978) 1.38
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett (1990) 1.36
Activation of macrophages for microbicidal and tumoricidal effector functions by soluble factors from EL-4, a continuous T cell line. Infect Immun (1983) 1.35
Differential regulation of class II MHC determinants on macrophages by IFN-gamma and IL-4. J Immunol (1989) 1.34
Granuloma formation in lungs of mice after intravenous administration of emulsified trehalose-6,6'-dimycolate (cord factor): reaction intensity depends on size distribution of the oil droplets. Infect Immun (1977) 1.32
Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets. J Natl Cancer Inst (1972) 1.32
Macrophage activation for tumor cytotoxicity: analysis of intermediary reactions. J Reticuloendothel Soc (1979) 1.31